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Abstract. Around half of the population of Afghanistan resides in areas at risk of malaria transmission. Two species
of malaria (Plasmodium vivax and Plasmodium falciparum) account for a high burden of disease—in 2011, there were
more than 300,000 confirmed cases. Around 80–95% of malaria is P. vivax. Transmission is seasonal and focal, below
2,000 m in altitude, and in irrigated areas which allow breeding of anopheline mosquito vectors. Malaria risk is strati-
fied to improve targeting of interventions. Sixty-three of 400 districts account for ∼85% of cases, and are the target of
more intense control efforts. Pressure on the disease is maintained through case management, surveillance, and use of
long-lasting insecticide-treated nets. Plasmodium vivax treatment is hampered by the inability to safely treat latent
hypnozoites with primaquine because G6PD deficiency affects up to 10% of males in some ethnic groups. The risk of
vivax malaria recurrence (which may be as a result of reinfection or relapse) is around 30–45% in groups not treated
with primaquine but 3–20% in those given 14-day or 8-week courses of primaquine. Greater access to G6PD testing
and radical treatment would reduce the number of incident cases, reduce the infectious reservoir in the population,
and has the potential to reduce transmission as a result. Alongside the lack of G6PD testing, under-resourcing and
poor security hamper the control of malaria. Recent gains in reducing the burden of disease are fragile and at risk of
reversal if pressure on the disease is not maintained.
MALARIA EPIDEMIOLOGYAND RISK
IN AFGHANISTAN
Malaria occurs at altitudes below 2,000 m above sea level,
and is most prevalent in snow-fed river valleys and areas used
for growing rice. Transmission of Plasmodium vivax malaria
takes place in May/June–November, with negligible transmis-
sion occurring between December and April. However, many
P. vivax infections relapse during the spring season and this
may give rise to a peak of clinical cases. The Plasmodium
falciparum peak is shorter in August–October. The seasonal-
ity and relative low prevalence of malaria (which rarely
exceeds 10% in the most endemic areas) results in a popula-
tion only partly immune to malaria, with children and teen-
agers carrying most of the burden. Plasmodium falciparum is
particularly unstable in this region, at the edge of its range,
and can fluctuate markedly from year to year depending
on climatic variation. Because of the infectious reservoir of
hypnozoites and the ability of the disease to develop at lower
temperatures in the vector, P. vivax affects a larger geograph-
ical area of the country than P. falciparum.
Protracted wars from 1979 to 2002 had a significant influ-
ence on malaria transmission.1 The combination of an almost
complete breakdown of health services and mass popula-
tion movements resulted in an increase in malaria caseload
from 40,000 to 80,000 per year in the 1970s to an estima-
ted 2.5–3 million cases in 2002. This was compounded by
the emergence of chloroquine-resistant P. falciparum, which
changed the ratio of the two species to about 50:50 in
some areas. With the introduction of effective treatments
(first, sulfadoxine–pyrimethamine [SP], then artemisinin com-
bination therapy [ACT] using SP and artesunate [AS]), the
proportion of cases caused by P. falciparum has decreased
from 13% in 2002 to 7% of confirmed cases in 2007 (6,283
cases), remaining at this level until 2014 (5,983 cases) (Figure 1).
The health system has improved markedly and expanded,
predominantly with funding from international donors. The
number of basic health facilities in Afghanistan increased
from 1,249 in 2004 to 2,015 facilities in 2010. The number of
facilities able to diagnose malaria using a parasite-based test
(mostly light microscopy) has also increased—more than 200
have been installed in clinics since 2004 in highly endemic
areas. Normally, an improvement of case detection (i.e., from
expanded services) would lead to an increase in reported
cases as an artifact of improved surveillance. In Afghanistan’s
case, the consistency in the number of cases reported through
the Health Management and Information System from
2004 to 2014 probably reflects an actual decrease in malaria
incidence overall—numbers reported into the HMIS have
remained constant, but the number of facilities reporting
malaria cases into the surveillance system from endemic areas
has increased.
Studies in the northern province of Kunduz in 2009, among
basic health centers have shown slide positivity rate to be
very low (< 0.1%) when slides are double read and confirmed
by polymerase chain reaction (PCR) analysis.2,3 In the same
study, by contrast, the eastern province of Nangarhar had a
slide positivity rate of around 25%. Most of these cases were
vivax malaria (98.7%, N = 446) versus six cases of falciparum
malaria from June to September 2009.
In keeping with most settings, clinic microscopy in low-
endemicity settings tends to overdiagnose malaria. The same
studies in Kunduz and Nangarhar showed that as many as
80% of cases diagnosed in the clinics are false positives.
Therefore, the burden of disease appears to be decreasing
when viewed nationally.
Vivax malaria remains the major cause of malaria morbid-
ity in Afghanistan. Reliable statistics regarding malaria mor-
tality do not exist, although 32 deaths were reported in 2014.
It is impossible to discern whether any deaths are attribut-
able to vivax malaria because the reporting system does not
differentiate the cause of death by species. It is assumed that
any malaria death is attributable to falciparum malaria, but
underreporting of vivax mortality is well documented.4
Afghanistan’s malaria risk is heterogeneous and associated
with environmental and human factors. The reduction in
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overall disease (e.g., in the North) has led to pockets of dis-
ease in foci. The improved surveillance and mapping of
malaria has allowed assessment of the distribution of disease.
In 2006, a risk-mapping exercise was undertaken to identify
districts with high environmental risk of malaria.5
These areas are receptive to malaria transmission, but
many of these areas currently have little active transmission.
To improve targeting of malaria control resources, the risk-
mapping data have been combined with recent routine
reporting data on incidence and slide positivity rate to give
risk models at district level (Figure 2). For program delivery
purposes, under the National Malaria Strategic Plan, the
country has been divided into four risk strata: Stratum 1 dis-
tricts (shown in red in Figure 2) with current ongoing high
transmission, and incidence > 5 cases per 1,000 population
per year. This comprises 63 of Afghanistan’s 400 districts,
contributing 84% of nationally reported malaria cases in
2013. Stratum 1 has a population of ∼3,000,000; Stratum 2
districts (incidence 1–5/1,000/year) with previous high trans-
mission, which are receptive to transmission (138 districts);
Stratum 3 districts with low transmission (incidence < 1/
1,000/year) but with a risk of epidemics (96 districts); and
Stratum 4 districts with no transmission but with clinical
cases imported from other areas (103 districts), which are
either too high or too arid and have never had active trans-
mission. This more detailed malaria stratification underpins
FIGURE 1. Number of confirmed cases of Plasmodium vivax (primary axis) and Plasmodium falciparum (secondary axis) in Afghanistan,
2002–2014.
FIGURE 2. Malaria endemicity in Afghanistan at district level.
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resource allocation for malaria control allowing a strategy of
intensive focal control of disease at those areas with the
highest burden.
MALARIAVECTORS AND VECTOR CONTROL
Recent efforts to improve data on vectors, vector control,
and insecticide resistance have enhanced knowledge of vec-
tor bionomics and vector control in Afghanistan.
An insecticide susceptibility survey conducted in 2010
highlighted the diverse distribution of primary and second-
ary vectors among several entomological sentinel sites in
Afghanistan: Anopheles superpictus in Balkh (north) and
Herat (western Afghanistan), Anopheles pulcherrimus, Anoph-
eles hycranus, and An. superpictus in Kunduz and Badakshan
(northeast), and Anopheles stephensi, Anopheles subpictus and
Anopheles culicifacies in Nangarhar (eastern region).
An extensive 18-month surveillance project from May
2008 to 2010 in and around Jalalabad city (Nangarhar Prov-
ince, in the east of the country), in a high-transmission area
of Stratum 1, showed the temporospatial distribution of mos-
quito fauna in four ecological zones (rice-growing agricul-
tural land, non-rice-growing agricultural land, river margin,
and peri-urban areas)6 (Figure 3).
The study incriminates An. stephensi as the predominant
vector, exhibiting strong zoophilic behavior7,8 and with a
greater presence in animal sheds than in human habitations.
Anopheles stephensi has been shown to be a primary vector
of P. vivax (REF, Rowland).7 Abundance and species com-
position varied across the four ecological zones and included
the following known vector species: An. culicifacies, Anoph-
eles fluviatilus, Anopheles annularis, An. pulcherrimus, and
An. superpictus. The relative role of these species in trans-
mission of P. vivax and P. falciparum has not been fully stud-
ied in Afghanistan.
The country’s first ever comprehensive assessment on the
status of insecticide susceptibility among malaria vectors was
conducted in 2010. The survey examined the susceptibility of
wild caught Anopheles to three classes of insecticides (pyre-
throids, carbamates, and organochlorines) in five provinces.
The survey observed reduced susceptibility to all three clas-
ses of insecticides in Afghanistan, originating mainly in the
eastern region (Nangarhar).8
Afghanistan has adopted integrated vector management
(IVM) as part of the National Malaria Strategic Plan. This
approach relies heavily on intersectorial collaboration to
implement control measures based on factors which influ-
ence vector biology, transmission, and morbidity. An IVM
steering committee was formed in 2010, which comprised
members from key line Ministries such as Ministry of Agri-
culture, Irrigation and Livestock, Water and Power, Educa-
tion, and Women’s Affairs. However, little movement has
been made toward practical steps for management of insecti-
cide resistance.
Over the years, operational capacity building within the
National Malaria and Leishmaniasis Control Programme
(NMLCP) has improved through support of a range of
donors to improve surveillance and undertake operational
research projects. Efforts have now been harnessed to
achieve “soft” and “hard” capacity development through
the construction of insectaries, entomology laboratories, in
Jalalabad, Kunduz, and in the future, Kabul. In addition to
this, molecular diagnostics capacity building has been pro-
vided to give the first dedicated PCR and enzyme-linked
immunosorbent assay laboratories in the NMLCP.
Capacity building of the entomology department continues
to be an ongoing process to increase the abilities of the pro-
vincial program staff, enabling better surveillance of vectors,
and insecticide resistance.
Long-lasting insecticide-treated nets (LLINs) are the
mainstay of vector control in Afghanistan. In the last 4 years,
more than 4,350,000 LLINs have been distributed with
around 4 million distributed in high-burden districts of Stra-
tum 1 provinces under this new strategy.
Afghanistan has adopted free house-to-house distribution
of LLINs using a voucher system. Before the most recent
risk classification (see above), this intervention was targeted
at the population of 14 Stratum 1 provinces leading to an
impressive increase in LLIN coverage rates at household
and individual levels. A recent study conducted by the
NMLCP9 described high coverage (> 60% households with
at least one net in highly endemic areas), retention (> 90%
FIGURE 3. Relative abundance of Anopheles species in peri-urban and rural areas around Jalalabad city, Afghanistan, 2008–2010.
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of nets available 1 year after distribution), and high use of
insecticide-treated nets (ITNs) in targeted areas (of those
with a net, > 85% reported using them the night before). A
recent study has evaluated the longevity of LLINs under
operational conditions and shows that integrity and survival of
LLINs was high after 4 years of use (unpublished report).9
Funding constraints have led to a change in strategy with
universal coverage with LLINs being targeted at the 64 most
highly endemic districts in the country. In other areas where
the aim was previously for universal coverage, targeted dis-
tribution is being undertaken to prioritize pregnant women
and children under 5 years of age. This is likely to lead to a
decrease in population coverage in those areas in the coming
years as coverage rates are subject to attrition as LLINs go
beyond use.
LLINs are less effective at reducing the incidence of
vivax malaria than that of falciparum malaria because
relapse cases occur regardless of the use of an LLIN. This
possibly accounts for the persistence of vivax as the main
species when coverage of LLINs is high. A trial conducted in
Pakistan in the 1990s showed a protective efficacy of ITNs of
62% against falciparum malaria versus 42% against vivax.10
DIAGNOSIS AND TREATMENT OF MALARIA
Diagnosis and treatment of malaria is integrated into the
Basic Package of Health Services in endemic areas in
Afghanistan and so is provided free of charge. Microscopic
diagnosis and rapid diagnostic tests (RDTs) are both in use,
though clinical diagnosis without parasitological confirmation
remains common at the level of the community health
worker and in low-endemic strata. This approach leads to
very high levels of overprescription of antimalarials with
> 99% of malaria-negative fever patients being incorrectly
treated with an antimalarial drug in very low endemic areas
of northern Afghanistan.2 RDTs have been demonstrated to
have advantages over both clinical diagnosis and micros-
copy,11,12 although both microscopy and RDTs suffer from
low sensitivity and can lead to species misclassification.13
RDTs have also demonstrated utility when deployed at com-
munity level though the large network of community health
workers in the country.
The biggest challenge to providing effective case-manage-
ment services will be to maintain a sustained supply of tests
which can reliably distinguish between P. vivax and P. falcip-
arum. Because of resource constraints and a focus on malaria
control (rather than local elimination), RDTs are being prior-
itized for use only in highly endemic districts. Recent data
from 22 clinics in Afghanistan suggest that microscopy
performance is suboptimal in both established laboratories
and newly installed laboratories.2,3 Microscopists in both
settings consistently overdiagnosed malaria (20–25% false-
positive rate). There were also deficiencies in diagnosis of
malaria in those with low parasite density (10% false-
negative rate) and in detecting the rare cases of falciparum
among many negative and a majority of vivax slides. The
performance was also highly variable between clinics, indi-
cating a need for constant training and support to quality
assurance and control.
Afghanistan’s treatment guidelines have been guided by
local evidence from clinical trials and are based on World
Health Organization–Eastern Mediterranean Regional Office
guidelines. The clinical trials were prompted by insupportable
levels of chloroquine resistance in P. falciparum malaria in
the late 1980s13; in 1989, the failure rate of chloroquine- and
amodiaquine-treated P. falciparum malaria has risen to more
than 60% overall and was as high as 90% in Jalalabad.14
Trials continued into the use of the ACT, SP and AS 15,16
which was adopted for first-line treatment and also shown to
be effective against vivax malaria.17
The status of SP resistance in falciparum malaria remains
a concern, because the current combination with AS may
mask any clinically observable resistance to SP. Molecular
analysis of P. falciparum isolates has been conducted and will
continue—a recent survey identified drug resistance alleles
in increasing proportions.18 The combination remains effec-
tive after 10 years of use.19 Additional clinical trials may
identify a different ACT (for example dihydroartemisinin–
piperaquine), which could be used in all malaria cases regard-
less of species.20
For treatment of vivax malaria, trials have also demon-
strated the continued efficacy of chloroquine to treat acute
P. vivax cases. The efficacy of primaquine for radical cure of
P. vivax is high, with PQ given over 14 days or 8 weeks
preventing 60–90% of relapse cases,21,22 (Table 1). A trial
also showed the poor efficacy of the 5-day regimen and led to
its eventual abandonment across Asia.23 An often cited reason
for the failure of primaquine is a lack of patient adherence
to treatment, but a single trial in an Afghan population in
Afghanistan showed that individuals with vivax malaria read-
ily comply with a 14-day primaquine regimen if given appro-
priate instructions.21 However, despite the overwhelming
evidence in favor of its efficacy, routine radical treatment
TABLE 1
Risk and odds ratios for relapse with vivax malaria from randomized control trials in Afghanistan and Pakistan (in Afghan refugees) on
PQ treatment
Study Period of observation (months) Treatment arm* Relapse risk Odds ratio (95% confidence interval)† P value
Leslie and others22 11 Placebo 22/71 (31.0%) 1
11 14-day PQ 1/55 (1.8%) 0.01 (0.002–0.1) 0.001
11 8-week PQ 4/75 (5.1%) 0.05 (0.01–0.2) 0.001
Leslie and others21 9 Placebo 86/212 (40.6%) 1
9 14 day (supervised) 40/211 (19.0%) 0.35 (0.21–0.57) 0.01
9 14-day (unsupervised) 34/173 (19.7%) 0.37 (0.23–0.59) 0.01
Rowland and others23 12 placebo 49/100 (49%) 1
12 14-day PQ 32/100 (32%) 0.6 (0.46–0.92) 0.014
PQ = primaquine.
*All groups received chloroquine.
†vs. placebo in the same trial.
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using primaquine is almost never used because G6PD testing
of malaria patients remains unavailable.
As in some vivax-endemic countries and in concordance
with current WHO guidelines,24 the treatment guidelines
provide a gold standard that is largely unattainable. In a case
where there is a huge gap between policy and practice, the
guidelines require treatment of vivax relapses with prima-
quine, stipulating that “The G6PD status of patients should
be used to guide administration of primaquine for preventing
relapse” but neither routine testing for G6PD deficiency nor
primaquine is made available. Although the guideline is
based on the several trials conducted in the region,21–23 the
reality is that it has no realistic prospect of guidelines being
adhered to unless G6PD deficiency can be readily diagnosed
by treating clinicians.
Plasmodium vivax in Afghanistan has a long latency
period before relapse. In one study, the time to the first
recurrent episode was 66–74 days and there was no differ-
ence in the time period between those treated with 14-day
primaquine and those who were untreated.21–23 This long
latency period is what enables the subtropical strain of vivax
to survive between transmission periods and may partially
explain the longer lag-time to effective control.
The difference in incidence of malaria between those
treated and those not treated with effective doses of prima-
quine (Table 1) indicates a protective efficacy of between
99% and 60% in those treated versus untreated with prima-
quine. The relapse risk over a long period of follow-up
(9, 11, and 12 months in three trials) indicates that up to half
of incident malaria cases may be due to relapse episodes.
The main confounder that makes it impossible (at the present
time) to clearly differentiate between relapses and new
episodes or treatment failure is the inability to distinguish
between new infections and relapses so it is not possible to
define the burden of relapse with certainty. But in areas of
very low transmission (such as the 2008 study in Table 1),
there is a greater effect than in the earlier studies during times
and in places of higher transmission. Thus, the impact of
wide-scale use of primaquine would be to prevent a significant
proportion of cases that result from relapses and to dramati-
cally reduce transmission by reducing the infectious reservoir.
Adequate treatment of vivax malaria relapses is therefore
now the main limitation in provision of effective treatment.
If the gold standard treatment includes antirelapse therapy
(primaquine), then almost none of Afghanistan’s vivax
malaria cases are adequately treated because of the absence
of G6PD testing. G6PD deficiency is high in certain ethnic
groups (up to 10% amongst male ethnic Pashtuns), and about
4% at the population level.25,26 The predominant G6PD
genotype is the Mediterranean subtype, which is moderate to
severe in the presence of hamolytic factors (e.g., primaquine,
dapsone). This makes the risk of providing primaquine too
high for widespread use without routine testing for G6PD
deficiency, even though there is some preliminary evidence
that G6PD deficiency is protective against infection with
vivax malaria.27 The protective effect of G6PD is from a sin-
gle case-control study and needs confirming in further stud-
ies. Even so, the effect is not absolute; so while it does
potentially reduce the risk of hemolysis, it does not negate it
completely. Little is known about the interaction of prima-
quine at therapeutic doses within females with heterozygous
deficiency. Because heterozygous females produce a mixed
population of deficient and nondeficient red cells (lyoniza-
tion), it is unknown whether use of primaquine is safe in this
group. Tests that can identify heterozygous females are not
available at clinic level, but tests that can identify females
with low G6PD deficiency could be used.
CONCLUSIONS
Malaria control has reduced the incidence of disease over
the last 15 years, with a rapid decline in P. falciparum
malaria coinciding with an increase in the availability and
use of ITNs and the introduction of more effective treat-
ments. However, the same impact has not been seen in vivax
malaria, which makes up the majority of malaria. Plasmo-
dium vivax is currently the major challenge. Its control and
elimination will be slower if conventional tools like LLIN
and treatment of acute cases are not accompanied by an
attack on the hypnozoite reservoir. Effective use of G6PD
testing may allow improved access to primaquine, which
would, in turn, reduce the ability of the parasite to maintain
its infectious reservoir.
Reductions in available resources for malaria control or
worsening of security could both have a major impact on
the control and elimination of disease. Much of Afghanistan
remains capable of supporting transmission (i.e., with the
presence of vectors and humans) so reducing the pressure on
the disease is likely to lead to resurgence. The widespread use
of antirelapse therapy is likely to rapidly reduce the burden of
disease, but this strategy relies on the availability of G6PD
tests. In those who cannot be prescribed radical cure (preg-
nant and lactating women, infants, and those with G6PD defi-
ciency), full protection through the use of ITNs is required.
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